AnaptysBio, Inc. Common Stock (ANAB) Financials
Key financial figures for AnaptysBio, Inc. Common Stock (Q2 2026).
AnaptysBio, Inc. reported revenue of $27.5 million for Q2 FY2026, up 23.5% from the same period a year earlier. Net income was $183.9 million, or $5.11 per share. Operating margin came to 243.59%, against -117.55% a year earlier. Across the last 5 reported quarters, quarterly revenue has risen from $22.3 million in Q2 FY2025 to $27.5 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for AnaptysBio, Inc. are on the SentiSense financials page.
- Revenue
- $27M
- Net Income
- $184M
- EPS
- $6.28
- Total Assets
- $317M
- Operating Cash Flow
- -$27M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $27M | $184M | $5.11 | 243.59% | |
| Q1 FY2026 | $26M | -$53M | -$1.84 | -135.53% | -$26M |
| Q4 FY2025 | $108M | $50M | $1.58 | 61.8% | $98M |
| Q3 FY2025 | $76M | $15M | $0.52 | 45.47% | -$27M |
| Q2 FY2025 | $22M | -$39M | -$1.34 | -117.55% | -$40M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $235M | -$13M | -$0.44 | 20.42% | $20M |
| FY2024 | $91M | -$145M | -$4.92 | -125.93% | -$136M |
| FY2023 | $17M | -$164M | -$6.08 | -958.27% | -$122M |
Frequently asked questions
What was AnaptysBio, Inc.'s revenue last quarter?
AnaptysBio, Inc. reported revenue of $27.5 million for Q2 FY2026, up 23.5% from the same period a year earlier.
Is AnaptysBio, Inc. profitable?
Yes. AnaptysBio, Inc. reported net income of $183.9 million for Q2 FY2026, a net margin of 668.95% on revenue.
How has AnaptysBio, Inc.'s margin trended?
Operating margin was 243.59% in Q2 FY2026, compared with -117.55% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How many quarters of AnaptysBio, Inc. financials does SentiSense hold?
SentiSense holds up to forty quarters and twenty fiscal years of income statement, balance sheet and cash flow history for ANAB. The 5 most recent quarters are summarised above.
Full income statement, balance sheet and cash flow for AnaptysBio, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.